FDAnews
www.fdanews.com/articles/131598-heart-risks-prompt-change-to-label-for-genentech-8217-s-hiv-drug-invirase

Heart Risks Prompt Change to Label for Genentech’s HIV Drug Invirase

November 3, 2010
Labeling for Genentech’s HIV drug Invirase must now warn patients that taking it with Abbott’s Norvir, another antiviral drug, could potentially result in life-threatening cardiovascular side effects. Combining the two drugs could cause prolongation of the QT and PR intervals, which could lead to a condition known as torsades de pointes, an abnormal heart rhythm that may potentially progress to a life-threatening irregular heart beat, ventricular fibrillation, the FDA said.
Washington Drug Letter